Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FibroGen Announces Topline Results From Two Late-Stage Pamrevlumab Pancreatic Cancer Studies; Pamrevlumab Arm Of Precision PromiseSM Study In Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint

Author: Benzinga Newsdesk | July 30, 2024 04:15pm

Pamrevlumab arm of the Precision PromiseSM study in metastatic pancreatic cancer, sponsored and conducted by the Pancreatic Cancer Action Network (PanCAN), did not meet the primary endpoint of overall survival as determined by the protocol pre-specified Bayesian statistical analysis
LAPIS study in locally advanced, unresectable pancreatic cancer, sponsored by FibroGen, did not meet the primary endpoint of overall survival
Pamrevlumab was generally safe and well tolerated across both studies, with no clinically meaningful difference in overall safety vs. control arms
Company to implement immediate and significant cost reduction plan in the U.S.
- Terminate pamrevlumab research and development (R&D) investment and expeditiously wind down remaining obligations
- Reduce U.S. workforce by approximately 75%

Posted In: FGEN